EUVIMEDEUVIMED entdecken
Crossref

Free Fatty Acids Link Residual Lipid and Thrombotic Risk via Impairment of Aspirin Antiplatelet Effects

Philipp Mourikis, Saif Zako, Carolin Helten, Laura Wildeis, David Beenken, Marcel Benkhoff, Christoph Dücker, Lisa Dannenberg, Norbert Gerdes, Tobias Zeus, Malte Kelm, Thomas Hohlfeld und 1 weitere

Thrombosis and Haemostasis · 2026-11 · 126 (11) · 1105-1112

DOI: 10.1055/a-2746-4552 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 04.12.2025. Verfasst von Philipp Mourikis und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany. Hauptthemen laut MEDLINE: Aspirin, Platelet Aggregation Inhibitors, Fatty Acids, Nonesterified, Thrombosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft, Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf, Heinrich-Heine-Universität Düsseldorf.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insufficient lipid-lowering therapy is associated with residual cardiovascular risk. Low-density lipoprotein (LDL) is well known to promote atherosclerosis and cardiovascular disease (CVD) and during lipoprotein metabolism, free fatty acids (FFA) are generated. Besides this, residual thrombotic risk occurs in patients with impaired pharmacodynamic response to aspirin—so-called high on-treatment platelet reactivity (HTPR). Until now, it is not known if there is a mutual link. For in vitro analyses, blood from healthy donors was used and incubated with different concentrations of LDL, FFA, and acetylsalicylic acid. Arachidonic acid (AA)-induced light transmittance aggregometry (LTA), thromboxane (TX) formation, and cyclooxygenase (COX)-1 activity were measured. In a cross-sectional analysis, aspirin antiplatelet effects, and LDL and FFA concentrations were measured in 612 aspirin-treated CVD patients. In vitro administration of LDL and FFA impaired aspirin antiplatelet effects. In patients, FFA levels were associated with HTPR to aspirin. FFA levels and plasma LDL correlated with AA-induced platelet aggregation. Statin medication improved aspirin antiplatelet effects. AA-induced platelet aggregation was decreased in patients with statin medication. In this study, we were able to demonstrate a link between residual lipid and thrombotic risk in patients with cardiovascular disease. We could show that LDL and FFA impair pharmacodynamic response to aspirin at the level of COX. Statin therapy improved aspirin antiplatelet effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinPlatelet Aggregation InhibitorsFatty Acids, NonesterifiedThrombosisBlood PlateletsHumansPlatelet AggregationFemaleMaleCross-Sectional StudiesMiddle AgedLipoproteins, LDLArachidonic AcidCyclooxygenase 1AgedPlatelet Function TestsHydroxymethylglutaryl-CoA Reductase InhibitorsRisk FactorsAdultThromboxanesCardiovascular Diseases

Substanzen

AspirinPlatelet Aggregation InhibitorsFatty Acids, NonesterifiedLipoproteins, LDLArachidonic AcidCyclooxygenase 1Hydroxymethylglutaryl-CoA Reductase InhibitorsThromboxanesPTGS1 protein, human

Autor:innen und Institutionen

  • Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Dusseldorf, Germany.
  • Institute of Analytical Chemistry, University of Vienna, Vienna, Austria.
  • Institute for Clinical Pharmacology, University Medical Center, Georg-August University, Göttingen, Germany.
  • Cardiovascular Research Institute Düsseldorf (CARID), Düsseldorf, Germany.
  • Institute for Pharmacology and Clinical Pharmacology, Heinrich Heine University, Dusseldorf, Germany.
  • National Heart and Lung Institute, Imperial College London, London, United Kingdom.

Förderung

  • Deutsche Forschungsgemeinschaft
  • Medizinische Fakultät, Heinrich-Heine-Universität Düsseldorf
  • Heinrich-Heine-Universität Düsseldorf

Zitieren

APA

Mourikis, P., Zako, S., Helten, C., Wildeis, L., Beenken, D., Benkhoff, M., Dücker, C., Dannenberg, L., Gerdes, N., Zeus, T., Kelm, M., Hohlfeld, T., & Polzin, A. (2026). Free Fatty Acids Link Residual Lipid and Thrombotic Risk via Impairment of Aspirin Antiplatelet Effects. Thrombosis and Haemostasis, 126(11), 1105-1112. https://doi.org/10.1055/a-2746-4552

Vancouver

Mourikis P, Zako S, Helten C, Wildeis L, Beenken D, Benkhoff M, et al. Free Fatty Acids Link Residual Lipid and Thrombotic Risk via Impairment of Aspirin Antiplatelet Effects. Thrombosis and Haemostasis. 2026;126(11):1105-1112. doi:10.1055/a-2746-4552

BibTeX
@article{Mourikis2026,
  author = {Mourikis, Philipp and Zako, Saif and Helten, Carolin and Wildeis, Laura and Beenken, David and Benkhoff, Marcel and Dücker, Christoph and Dannenberg, Lisa and Gerdes, Norbert and Zeus, Tobias and Kelm, Malte and Hohlfeld, Thomas and Polzin, Amin},
  title = {Free Fatty Acids Link Residual Lipid and Thrombotic Risk via Impairment of Aspirin Antiplatelet Effects},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  volume = {126},
  number = {11},
  pages = {1105--1112},
  doi = {10.1055/a-2746-4552}
}
Kostenlos starten →